Shares of Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) have been on the comeback trail in a significant way, rallying as much as 105% since the lows recorded in December at $1.48 on an intraday basis. To further build out the book, the company just announced that it has entered into a license with Indena S.p.A. of Milan, Italy, bearing certain exclusivity rights in Canada to use Indena’s cannabidiol extraction technology, and contract manufacturing services for CBD extraction.
According to the release, Emerald has also obtained exclusive use of Indena’s proprietary Phytosome technology for the purpose of developing novel cannabinoid-based products with superior utility, subject to a minimum volume agreement.
Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) trumpets itself as a licensed producer of medical marijuana under the Access to Cannabis for Medical Purposes Regulations, which allows the company to produce and sell medical marijuana and cannabis oils to clients and other licensed producers.
Individuals may become clients of the company by registering with the company through its secure online portal or via telephone after the individual has received a medical document signed by a licensed health care practitioner setting out the daily quantity of dried marijuana, in grams, that the practitioner authorized for the person.
According to company materials, “Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) operates through Emerald Health Botanicals Inc., a wholly owned subsidiary and Licensed Producer under the Access to Cannabis for Medical Purposes Regulations. Botanicals is authorized to produce and sell both dried medical cannabis flower and medical cannabis oil in Canada. Botanicals currently operates an indoor facility in Victoria, BC, and is progressing on expansion plans for a 32-acre property in Metro Vancouver and a partnership with Village Farms, called Pure Sunfarms, utilizing a 25-acre existing greenhouse complex in Delta, BC. Botanicals is one of Canada’s most medically focused licensed producers, with a team highly experienced in life sciences product development and large-scale agribusiness. Its vision is to be a leading provider of cannabis products through its production capabilities, proprietary genetics, value-added products and branding, and superb customer experience. Emerald Health Therapeutics is associated with the Emerald Health group, which comprises multiple companies advancing diverse botanical, nutraceutical and pharmaceutical products that may provide wellness and medical benefits by interacting with the body’s endocannabinoid system.”
Find out when $EMHTF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, EMHTF just announced that it has entered into a license with Indena S.p.A. of Milan, Italy, bearing certain exclusivity rights in Canada to use Indena’s cannabidiol extraction technology, and contract manufacturing services for CBD extraction.
We’ve witnessed 37% piled on for shareholders of the listing during the trailing month. What’s more, the company has benefitted from a jump in recent trading volume to the tune of approaching 130% above the average volume levels in play in this stock over the longer term.
“Emerald is one of the few Licensed Producers in Canada focused on applying proprietary innovation to improve the medical applications of cannabinoids, which is fully aligned with Indena’s scientific approach to phytochemical research,” said Stefano Togni, Business Development and Licensing Director of Indena. “We believe that both companies’ approaches to quality and innovation will create an exciting partnership that will add value to the industry and better serve patients and consumers who look for excellence in their products and predictive health outcomes.”
Now commanding a market cap of $416.55M, EMHTF has a significant war chest ($52.9M) of cash on the books, which stands against about $30.7M in total current liabilities. One should also note that debt has been growing over recent quarters. EMHTF is pulling in trailing 12-month revenues of $1.3M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 51.9%. This may be a very interesting story and we will look forward to updating it again soon. Sign-up for continuing coverage on shares of $EMHTF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $EMHTF, either long or short, and we have not been compensated for this article.